由XI因子Gly397Ser突变引起的血栓形成,具有增强的前凝活性
Yanyan Shao1,2, Yang Xu1,2, Min Xin1
1Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Thrombosis and haemostasis
|December 8, 2025
概括
一个新的XI因子 (FXI) 突变,Gly397Ser (G397S),在患有深静脉血栓症 (DVT) 的患者中被发现. 这种突变增强了FXI活性,导致凝血风险增加和对凝血分解的抵抗力.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 升高的XI因子 (FXI) 水平与静脉血栓塞栓症 (VTE) 风险的增加有关.
- 以前没有发现导致FXI水平升高的基因突变.
研究的目的:
- 为了研究一种新的致病性FXI突变,Gly397Ser (G397S),在患有深静脉血栓症 (DVT) 的患者中确定.
- 阐明FXI G397S突变导致血栓事件的分子机制.
主要方法:
- 患者基因测序以识别FXI突变.
- 在体外表达和功能性特征的FXI G397S突变蛋白.
- 酶动力学测试 (Km,kcat) 和使用聚离子,血和FXIIa.的激活研究.
- 对FXI对因子IX (FIX) 的活性和由蛋白酶Nexin 2 (PN2) 抑制的检测.
- 凝块溶解试验用于评估纤维解质耐药性.
主要成果:
- 在FXI G397S突变体中,FXI活性 (FXI:C) 与抗原 (FXI:Ag) 相比增加了2倍.
- 突变FXIa在存在氨酸时显著增加了催化效率 (kcat) 和通过血栓激活的强化.
- G397S突变赋予了对凝块溶解的耐药性,依赖于可激活血栓的纤维素分解抑制剂 (TAFI).
结论:
- FXI G397S突变主要通过增加激活来增强FXIa活性,从而导致持续的血栓生成.
- 这种高凝血状态,加上纤维溶解药物耐药性,是患者对DVT的倾向的基础.
- 确定了与FXI相关的血栓友的新型遗传原因.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K
01:29Venous Thrombosis III: Interprofessional Care
265
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
01:24Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
01:30Venous Thrombosis I: Introduction
310
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
310